Is There an Obesity Paradox for Outcomes in Atrial Fibrillation? A Systematic Review and Meta-Analysis of Non–Vitamin K Antagonist Oral Anticoagulant Trials
M Proietti, E Guiducci, P Cheli, GYH Lip - Stroke, 2017 - Am Heart Assoc
Background and Purpose—Obesity is a risk factor for all-cause and cardiovascular death
but, despite this, an inverse relationship between overweight or obesity and a better …
but, despite this, an inverse relationship between overweight or obesity and a better …
[HTML][HTML] Effectiveness and safety of dabigatran in atrial fibrillation patients with severe obesity: a real-world retrospective cohort study
Background Direct oral anticoagulants such as dabigatran are the preferred anticoagulant in
treating atrial fibrillation (AF) patients due to their effectiveness and safety. Whether this …
treating atrial fibrillation (AF) patients due to their effectiveness and safety. Whether this …
Evaluating the safety and effectiveness of direct oral anticoagulants compared with warfarin in very elderly patients with atrial fibrillation with and without low …
T Patil, S Ali, D Eppes, A Lee, N Jarmukli - Journal of Thrombosis and …, 2024 - Elsevier
Background Limited data exist on the safety and effectiveness of using direct oral
anticoagulants (DOACs) in patients with atrial fibrillation aged 80 years or more with and …
anticoagulants (DOACs) in patients with atrial fibrillation aged 80 years or more with and …
[HTML][HTML] Effectiveness and safety of rivaroxaban versus warfarin among nonvalvular atrial fibrillation patients with obesity and diabetes
MR Weir, YW Chen, J He, B Bookhart… - Journal of Diabetes and …, 2021 - Elsevier
Aims To compare clinical outcomes of rivaroxaban and warfarin in patients with nonvalvular
atrial fibrillation (NVAF) and concurrent obesity and diabetes. Methods Patients aged≥ 18 …
atrial fibrillation (NVAF) and concurrent obesity and diabetes. Methods Patients aged≥ 18 …
Direct oral anticoagulants in obesity: an updated literature review
J Sebaaly, D Kelley - Annals of Pharmacotherapy, 2020 - journals.sagepub.com
Objective: To review literature on the use of direct-acting oral anticoagulants (DOACs) in
patients with high body weight (BW) and/or high body mass index (BMI) and to make …
patients with high body weight (BW) and/or high body mass index (BMI) and to make …
Efficacy and Safety of Non–Vitamin-K Antagonist Oral Anticoagulants Versus Warfarin Across the Spectrum of Body Mass Index and Body Weight: An Individual …
BACKGROUND: The efficacy and safety of non–vitamin-K antagonist oral anticoagulants
(NOACs) across the spectrum of body mass index (BMI) and body weight (BW) remain …
(NOACs) across the spectrum of body mass index (BMI) and body weight (BW) remain …
[HTML][HTML] Effectiveness and safety of under or over-dosing of direct oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of 148909 patients …
NN Shen, C Zhang, N Wang, JL Wang… - Frontiers in …, 2021 - frontiersin.org
Background: In routine clinical practice, non-standard doses of direct oral anticoagulants
(DOACs) are commonly used in patients with atrial fibrillation (AF). However, data on the …
(DOACs) are commonly used in patients with atrial fibrillation (AF). However, data on the …
Pharmacokinetics and dosing regimens of direct oral anticoagulants in morbidly obese patients: an updated literature review
Y Zhao, M Guo, D Li, W Xu, C Pan… - Clinical and Applied …, 2023 - journals.sagepub.com
Data on the impact of morbid obesity (body mass index [BMI]≥ 40 kg/m2) on the
pharmacokinetics (PK), pharmacodynamics (PD) of direct oral anticoagulants (DOACs) are …
pharmacokinetics (PK), pharmacodynamics (PD) of direct oral anticoagulants (DOACs) are …
Adverse events in low versus normal body weight patients prescribed apixaban for atrial fibrillation
D DeCamillo, B Haymart, X Kong, S Kaatz… - Journal of thrombosis …, 2023 - Springer
Safety and efficacy of direct oral anticoagulants (DOAC) in low weight patients with atrial
fibrillation (AF) is unclear due to few low body weight patients enrolled in clinical trials. To …
fibrillation (AF) is unclear due to few low body weight patients enrolled in clinical trials. To …
Off-label under-and overdosing of direct oral anticoagulants in patients with atrial fibrillation: a meta-analysis
Background: Prescriptions of off-label under-and overdosing of direct oral anticoagulants
(DOACs) are common for patients with atrial fibrillation, but their efficacy and safety remain …
(DOACs) are common for patients with atrial fibrillation, but their efficacy and safety remain …